Promis Neuroscie Stock Price, News & Analysis

ProMIS Neurosciences (Nasdaq: PMN) reported a peer‑reviewed publication linking clinical efficacy of Aβ antibodies to selective binding of soluble toxic Aβ oligomers. The study found PMN310 preserved oligomer binding despite high monomer concentrations, showed no detectable plaque or vascular binding, and produced no microhemorrhages in high‑dose, chronic plaque‑bearing mice. ProMIS said PRECISE‑AD enrollment is on track to finish by end of 2025, with a 6‑month interim readout planned for Q2 2026 and top‑line results expected in Q4 2026.

ProMIS Neurosciences (Nasdaq: PMN) announced a peer‑reviewed cross‑trial analysis showing plasma pTau181/217 as a potential early predictive endpoint in Alzheimer’s trials. The analysis reported a strong group‑level correlation (≈ 0.78) between 6‑month plasma pTau changes and 12‑month CDR‑SB outcomes, an effect size on plasma pTau ~2.6× larger than clinical change, and simulations indicating well‑powered POC trials could require ~100 participants. ProMIS says these findings align with PRECISE‑AD’s biomarker‑centric design and support a planned blinded 6‑month biomarker readout, including pTau217, expected in Q2 2026.

ProMIS Neurosciences (Nasdaq: PMN) announced that CEO Neil Warma will speak at the 8th Annual Evercore Healthcare Conference on December 2, 2025. The appearance includes a fireside chat at 3:25 PM ET and investor one-on-one meetings.

A live webcast of the presentation will be available via the company Events page at www.promisneurosciences.com and will remain accessible for at least 30 days after the event.

ProMIS Neurosciences (Nasdaq: PMN) will effect a one-for-twenty-five reverse stock split of its common shares at 12:01 a.m. ET on November 28, 2025. The split will reduce outstanding shares from approximately 53,811,110 to approximately 2,152,444 and a new CUSIP 74346M505 will be assigned.

Proportional adjustments will be made to equity awards, options, warrants and exercise prices; fractional shares will be settled in cash. The board says the split is intended to increase the market price and cure a Nasdaq bid-price deficiency; Nasdaq extended the company’s compliance period to December 29, 2025.

ProMIS Neurosciences (Nasdaq: PMN) reported Q3 2025 results and corporate updates on Nov 12, 2025. The company said its Phase 1b PRECISE-AD trial of PMN310 is over 85% enrolled, with Cohorts 1 and 2 fully enrolled and Cohort 3 expected to complete enrollment before year-end.

PMN310 continues to show a favorable safety profile; the DSMB cleared progression to the third dose cohort. ProMIS expects 6-month interim data in Q2 2026 and final 12-month top-line results in Q4 2026. Cash was $15.4M at Sept 30, 2025, after July financing that generated ~$21.6M gross proceeds. Q3 R&D expense was $9.8M (Q3 2024: $2.6M); operating loss was $11.8M (Q3 2024: $4.4M).

ProMIS Neurosciences (NASDAQ: PMN) announced management will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on November 10, 2025. CEO Neil Warma and senior management will take part in a fireside chat from 11:00–11:25 AM ET and hold investor one-on-one meetings. A live webcast will be available via the company Events page at www.promisneurosciences.com and will remain accessible for at least 30 days after the event.

ProMIS Neurosciences (Nasdaq: PMN) appointed Slanix Paul Alex, Pharm.D., President and Portfolio Manager for Ally Bridge Group’s Public Equity strategy, to its Board of Directors on October 22, 2025. Dr. Alex brings sell-side and buy-side biotech investing experience, pharmacy credentials, and capital-markets expertise. Ally Bridge Group is described as one of ProMIS’ largest shareholders and recently invested in July 2025. The company cited planned PRECISE-AD data readouts for PMN310 in 2Q26 and 4Q26 and said Dr. Alex will support late-stage development planning.

ProMIS Neurosciences (NASDAQ: PMN) has received approval from its Data and Safety Monitoring Board (DSMB) to advance to the final dose escalation cohort in its Phase 1b PRECISE-AD clinical trial of PMN310 for Alzheimer's disease treatment. The trial has shown no cases of amyloid-related imaging abnormalities (ARIA) to date through Cohort 2.

The study, designed to enroll 128 patients, is proceeding from 10 mg/kg to 20 mg/kg dosing in the final cohort. The company remains on schedule to report 6-month interim data in Q2 2026 and 12-month top-line results in Q4 2026. PMN310 is specifically engineered to target toxic oligomers while avoiding amyloid plaque, potentially offering a safer treatment approach for Alzheimer's disease.

ProMIS Neurosciences (NASDAQ: PMN) reported significant progress in Q2 2025, highlighted by the FDA Fast Track Designation for PMN310, their lead Alzheimer's disease treatment candidate. The PRECISE-AD Phase 1b trial has achieved over 50% enrollment of planned 128 patients, with notably zero cases of ARIA (amyloid-related imaging abnormalities) and no dropouts, suggesting a favorable safety profile.

The company significantly strengthened its financial position, raising $21.6 million in gross proceeds in July 2025. Q2 financial results showed cash and equivalents of $4.5 million, with R&D expenses increasing to $8.7 million from $1.6 million year-over-year, primarily due to the PRECISE-AD trial. The company expects to report 6-month blinded interim results in Q2 2026 and final topline results in Q4 2026.